Subscribe to Search results

Dr Dale Lawrence of the Centers for Disease Control in the United States wrote to Dr Craske about the US cases of AIDS among people with haemophilia.

Published on:

Dr Rizza wrote to Dr Lane to confirm arrangements made for an informal meeting to be held on 15 December 1982 at BPL to discuss hepatitis free/hepatitis reduced coagulant factor concentrate.

Published on:

Dr Cash wrote to Dr Lane expressing his view that it is not "in the best interests of the NHS Fractionation Centres, at this time, to encourage the commercial manufacturers to undertake clinical trials with a view to obtaining product licences."

Published on:

Alpha Pharmaceutical issued a press release, which said: "The evidence suggests, although it does not absolutely prove, that a virus or other disease agent was transmitted to them in the Factor VIII concentrate, derived from pooled human plasma."

Published on:

Cases of AIDS in haemophilia patients in the United States were discussed in a UK Haemophilia Centre Directors Hepatitis Working Party meeting. Among the issues raised was the possibility that Factor 8 or other blood products administered to haemophilia patients "might be implicated."

Published on:

The topic of AIDS was discussed in a meeting of directors of the Scottish National Blood Transfusion Service and haemophilia centre directors. In the meeting, Dr Cash drew attention to recent articles in The Observer and The Lancet and circulated a MMWR extract.

Published on:

The topic of Factor 9 concentrates was discussed in a meeting of directors of the Scottish National Blood Transfusion Service and haemophilia centre directors. It was reported that studies of heat treatment, to reduce the hepatitis risk, were currently underway using Supernine.

Published on:

In a haemophilia reference centre directors meeting, it was noted that "there were some concern that the haemophilic population of the U.K. who had received American concentrates might be at risk" of AIDS. It was agreed that Dr Craske should draw up a form for the reporting of cases and to arrange for it to be circulated to all haemophilia centre directors.

Published on:

A meeting of the Haemostasis Club took place where Professor Jeanne Luscher presented on AIDS and set out treatment recommendations from the US.

Published on:

Drs Craske, Rizza and Bloom wrote to all haemophilia centre directors inviting them to report possible cases of AIDS.

Published on:

Dr Craske authored a report on AIDS, referring to the possibility that the agent for AIDS "might be present in the plasma pools used to prepare commercial factor VIII and IX concentrate manufactured from donor plasma collected in the U.S.A.".

Published on:

Dr Craske authored a guidance document for identifying possible cases of AIDS.

Published on:

A Form was drafted regarding U.K. Haemophilia Centre Directors Hepatitis Working Party's Surveillance of Possible Cases of the AIDS

Published on:

Kevin Slater was 20 years old when his AIDS symptoms were first identified and just 22 years old when he died in 1985.

Published on:

In his statement to the Haemophilia Society, Professor Bloom stated that he was "unaware of any proven case" of AIDS among people with haemophilia in the UK.

Published on:

The Communicable Disease Surveillance Centre ("CDSC") published a weekly report observing Kevin Slater's case as"This is the first report of AIDS in a patient with haemophilia in the United Kingdom known to CDSC."

Published on:

Dr Nicol Spence Galbraith (CDSC), notified the DHSS regarding the report of AIDS in a patient with haemophilia in the United Kingdom.

Published on:

Dr Galbraith (PHLS) concluded in a letter to Dr Ian Field (DHSS) that all products made from blood donated in the USA after 1978 should be withdrawn from use.

Published on:

Dr Walford, wrote a memo to Dr Field regarding Dr Galbraith's conclusion on the withdrawal of all blood products from donated blood in the USA.

Published on:

Professor Bloom stated in a letter to the haemophilia centres directors "I hope that it will be possible rapidly to vary the Product Licence for relevant imported products to take account of these recent developments."

Published on: